Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Go back to Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 55.78 +0.78 (1.42%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $55.00 | 52 Week High | $77.12 | |||
| Open | $55.37 | 52 Week Low | $49.03 | |||
| Day High | $56.19 | P/E | 36.22 | |||
| Day Low | $55.02 | EPS | $1.54 | |||
| Volume | 3,099,946 | |||||
